Study of resistance to lorlatinib in ALK-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at what happens when lung cancer stops responding to the drug lorlatinib, which is used as the first treatment for ALK-positive non-small cell lung cancer. It aims to find out why the drug stops working and what the next best treatment might be, which could help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have advanced or metastatic non-small cell lung cancer (NSCLC), confirmed by biopsy.
- Your tumor has confirmed ALK gene rearrangement (a specific type of lung cancer).
- You started lorlatinib as your first treatment for this cancer between April 2023 and April 2027.
- You have evidence that your cancer progressed (worsened) while on lorlatinib within 2 weeks before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
Hear when a new ALK-Positive NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.